Stock-Based Compensation: The estimated market value of stock options, warrants and other stock-based compensation given to employees and/or vendors.
Viking Therapeutics, Inc. (VKTX) had Stock-Based Compensation of $39.36M for the most recently reported fiscal quarter, ending 2026-09-30.
| Income Statement Financials | |
-- |
|
$-183.19M |
|
-- |
|
-- |
|
$187.11M |
|
$-187.11M |
|
$3.93M |
|
$-183.19M |
|
$-183.19M |
|
$-183.19M |
|
$-183.19M |
|
$-183.19M |
|
$-183.19M |
|
$-187.11M |
|
$-187.75M |
|
118.05M |
|
118.05M |
|
$-1.55 |
|
$-1.55 |
|
| Balance Sheet Financials | |
$973.00M |
|
-- |
|
$4.17M |
|
$977.17M |
|
$133.90M |
|
$250.66M |
|
$254.67M |
|
$388.57M |
|
$588.60M |
|
$588.60M |
|
$588.60M |
|
127.52M |
|
| Cash Flow Statement Financials | |
$-377.34M |
|
$256.14M |
|
$633.21M |
|
$165.81M |
|
$677.81M |
|
$512.00M |
|
|
Stock-Based Compensation |
$39.36M |
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
7.27 |
|
-- |
|
-- |
|
0.30 |
|
0.43 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-377.34M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-31.12% |
|
-31.12% |
|
-18.75% |
|
-21.83% |
|
$4.62 |
|
$-3.20 |
|
$-3.20 |
|